AGMT
  • Die AGMT
    • Über uns
    • Vorstand
    • Team
    • Partner
    • Karriere
    • Kontakt
  • Studien
    • Hodgkin Lymphom
      • HD21
      • AERN
    • Non-Hodgkin Lymphom
      • NHL-15B
      • DSHNHL_NIVEAU
      • ORACLE
    • Multiples Myelom
      • MM-2
      • MM-3
      • DSMM_XVII
    • Mammakarzinom
      • MBC-10
    • Kolorektalkarzinom
      • SAKK 41/14 Active-2
    • Pankreaskarzinom
      • DIsCOvER
    • COVID-19
      • INSERM_DisCoVeRy
  • Register
    • AIHA Registry
    • ALL Register
    • aMYELOIDr
    • BV NIS
    • HMA Register
    • MBC Register
    • NGS Register
    • PTCL Register
    • LungCA Register
    • COVID-19 Register
  • Veranstaltungen
    • AGMT Jahresmeeting
    • Breast Cancer Talk
    • GI Cancer Summit
  • Publikationen
  • News
    • News Übersicht
    • Newsletter
    • Presseaussendungen
    • News Archiv
  • Kontakt
  • AAA
  • Login
  • de
    Languages
    • en English
    • de Deutsch

Kolorektalkarzinom

  • SAKK 41/14 Active-2
SAKK 41/14 Active-2

SAKK 41/14 Active-2

Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy. A multicenter open label randomized controlled trial.

Synopsis

Short title: SAKK 41/14 Active-2

Title: Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy. A multicenter open label randomized controlled trial.

Status: open

Start: June 2016 (in Austria)

Coordinating Investigator: Univ. Prof. Dr. Josef Thaler (in Austria)

EudraCT Number: 2015-003733-10

ClinicalTrialsID: na

Number of patients: 300 (international)

Sponsor: SAKK (Swiss Group for Clinical Cancer Research), AGMT Sponsor representative in Austria

Design

All patients will undergo standard systemic therapy for metastatic colorectal cancer. Patients in the care-as-usual group are not actively encouraged to change their physical activity level e.g. to start a fitness program during chemotherapy.

The physical exercise ACTIVE-program describes a 12-week exercise program consisting of a combination of a bi-weekly aerobic exercise (cycle ergometer) supervised by a physical therapist and a self-paced increase in physical activity during daily life using a pedometer with a daily step goal as a motivational tool. The program will be individually tailored to each patient based on the training protocol and is aimed at increasing physical activity levels and cardiorespiratory fitness.

Primary objective:

To assess whether a structured physical activity program (PA) during palliative chemotherapy improves progression-free survival (PFS) and/or patient-reported outcomes (ESAS-r) in patients with metastatic colorectal cancer.

Primary endpoints:

The co-primary endpoints are PFS and patient-reported symptoms as measured by the ESAS-r (Edmonton Symptom Assessment System revised).

Secondary endpoints:
  • Efficacy
  • Chemotherapy-related endpoints and toxicities
  • Patient reported outcomes
  • Exercise endpoints

Inclusion/Exclusion criteria

Inclusion criteria (selected):
  • Written informed consent according to ICH/GCP regulations before randomization
  • Patients with histologically or cytologically confirmed colorectal carcinoma (CRC) who start palliative first-line systemic therapy for inoperable or metastatic disease.
    Note: Patients can be included before the start or within the first three weeks of first-line systemic treatment
  • Patients with histologically or cytologically confirmed colorectal carcinoma (CRC), who start first-line “conversion”-therapy for borderline resectable metastatic disease and will be reassessed for metastasectomy after 3-4 months of systemic treatment.
    Note: Patients can be included before the start or within the first three weeks of first-line systemic treatment
  • Patients who are diagnosed with metastatic disease and were initially treated with surgery and/or radiochemotherapy to the primary tumor are eligible (except if all disease sites/metastases have been removed)
  • Patients who have been curatively treated with histologically or cytologically confirmed nonmetastatic CRC previously and now relapse with metastatic disease are also eligible, irrespective of previous radiochemotherapy and/or adjuvant chemotherapy
  • Patients must have measurable disease on CT scan or MRI to be performed within 6 weeks before randomization (measurability criteria according to RECIST 1.1, non-nodal lesions ≥10 mm, lymph nodes ≥15mm) OR evaluable disease i.e. patient with nonmeasurable metastases but elevated serum tumor-marker (CEA at least >2xULN).
  • Command of written and spoken language allowing for informed consent and for filling in trial questionnaires
  • Baseline patient-reported outcomes (PROs) have been completed
  • WHO performance status 0-2
  • Age ≥18 years
Exclusion criteria (selected):
  • Pre-existing severe medical conditions precluding participation in a physical activity program as determined by the local investigator
  • Inability to ride a cycle ergometer e.g. for musculoskeletal reasons
  • Patients in whom all CRC metastases have been removed surgically

Studien
  • Studien
    • Hodgkin Lymphom
      • HD21
      • AERN
    • Non-Hodgkin Lymphom
      • NHL-15B
      • DSHNHL_NIVEAU
      • ORACLE
    • Multiples Myelom
      • MM-2
      • MM-3
      • DSMM_XVII
    • Mammakarzinom
      • MBC-10
    • Kolorektalkarzinom
      • SAKK 41/14 Active-2
    • Pankreaskarzinom
      • DIsCOvER
    • COVID-19
      • INSERM_DisCoVeRy
Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Firmensitz und Rechnungsadresse: Gentzgasse 60/21, 1180 Wien
Zweigstelle & Zustelladresse: Wolfsgartenweg 31, 5020 Salzburg
Firmenbuchnummer: FN 289548 g
UID-Nummer: ATU63467108
+43 662 640 44 12
+ 43 664 142 25 04
+43 662 640 44 14
office@agmt.at
Copyright © AGMT gemeinnützige GmbH
  • Impressum
  • Datenschutzerklärung
Wir verwenden Cookies, um Ihr Erlebnis auf unserer Website so angenehm wie möglich zu gestalten, um Inhalte und Anzeigen zu personalisieren, Funktionen für soziale Medien anbieten zu können und die Zugriffe auf unsere Website zu analysieren. Außerdem geben wir Informationen zu Ihrer Verwendung unserer Website an unsere Partner für soziale Medien, Werbung und Analysen weiter. Unsere Partner führen diese Informationen möglicherweise mit weiteren Daten zusammen, die Sie ihnen bereitgestellt haben oder die sie im Rahmen Ihrer Nutzung der Dienste gesammelt haben. Mit der weiteren Nutzung der Seite geben Sie die Einwilligung zu unseren Cookies. Weitere Informationen über unsere Datenerfassungspraktiken finden Sie in unserer Datenschutzerklärung.OK